These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.

 

RESEARCH

  • Liu W et al. Development of a neuroprotective potential algorithm for medicinal plants.  University of Rhode Island. Neurochem Int. 29 Sep 2016. 100: 164-177. - As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation. Bacognize showed the highest in anti-Aβ fibrillation in both methods.
  • Kumar et al. Efficacy of standardized extract of Bacopamonnieri (Bacognize®) on cognitive  functions of medical students: A six-week, randomized placebo-controlled trial.Evidence-Based Comp Alter Med. 2016 Sep 15. Vol 2016 (Art ID 4103423): 8pgs. DOI: 10.1155/2016/4103423 - In a randomized, placebo controlled crossover human clinical trial, administration of Bacognize® at 300mg/day to healthy medical students significantly improved (p<0.05) several parameters of cognitive function, including memory, focus, and attention. No adverse events were reported in either the Bacognize® or placebo groups.

  • Headapohl et al. Effects of Bacopa monnieri (Bacognize®) on memory and cognitive function in healthy older adults: A double-blind placebo-controlled study. Manuscript. - In a randomized, placebo controlled trial in older adults, positive trends in working memory, attention, and focus were seen in the Bacognize® group (300mg/day) compared to placebo. Further, no adverse events were reported in either the Bacognize or placebo groups.

  • Hingorani L et al. Sustained cognitive effects and safety of HPLC-stancardized Bacopa monnieri  (Bacognize®) extract: A randomized, placebo controlled clinical trial.  Planta Med. 2012. 78-PH22. DOI: 10.1055/s-0032-1320681 - In a randomized, placebo controlled trial in older adults, significant improvement in the Bacognize® group (300mg/day) was seen over placebo in short-term memory, processing speed, attention, and depression. Additionally, an effect was observed four weeks after administration discontinued. No adverse events were reported in either the Bacognize® or placebo groups.

  • Goswami S et al. Effect of Bacopa monnieri (Bacognize®) on cognitive function in patients.  Int J Collab Research Internal Med. 10 May 2011. 3(4): 285-293. ISSN: 1840-4529 - Improvement in the Bacognize® group (300mg/day) was seen over placebo in areas of cognitive function in this six-month clinical trial conducted on geriatric AD subjects. No adverse events were reported in either the Bacognize® or placebo groups.

  • Hall et al. Pharmacology of Bacopa monnieri (Bacognize®) at 5HT1a and 5HT2a receptors. Am Soc Pharmacog Absts. 2005. 83-85. Presented at 2005 Annual Mtg Am Soc Pharmacog, Corvallis, OR. - Pharmacology research on Bacognize and its isolated constituents showed strong regulation at serotonin receptors that are key for higher cognitive functions such as memory, mood, and focus.

  • Stough et al. Phytother Res. 2008 Dec. 22(12): 1629-34.

  • Calabrese et al. J Altern Complement Med. 2008 Jul. 14(6): 707-13.

  • Stough et al. Psychopharmacology (Berl). 2001 Aug. 156(4): 481-4.

  • Bacopa monnieri: Monograph. Altern Med Rev. 2004 Mar. 9(1): 79-85. Review.